The Latest Breaking News from BMY

Bristol-Myers Squibb has been lagging behind other drug manufacturers over the past three months, and analysts remain cautious about the stock's prospects.

The healthcare sector is expected to grow rapidly due to the growing need for precision drugs, the rising elderly population, government initiatives, and increasing chronic diseases. Against this backdrop, investors could consider buying fundamentally strong, undervalued healthcare stocks such as AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Gilead Sciences (GILD). Read…

The pharmaceutical industry is undergoing rapid growth and expansion, driven by rising medical needs, favorable regulatory measures, and the implementation of pharma 4.0. Hence, investors could snatch up quality pharma stocks Bristol-Myers Squibb (BMY), Spero Therapeutics (SPRO), and OptiNose (OPTN) for steady returns during market dips. Read more.

The pharmaceutical industry is experiencing rapid growth thanks to healthcare demand, regulatory initiatives, and technological adoption in drug discovery and development. Hence, it could be wise to invest in pharma stocks Ipsen (IPSEY), Bristol-Myers (BMY), and Taro Pharmaceutical (TARO) to drive your bottom line. These stocks are rated A (Strong…

The pharma industry is well-positioned to remain buoyed, owing to the rise in chronic diseases, a growing elderly population, and the integration of advanced technologies. Given this backdrop, quality pharma stocks Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ), Novartis AG (NVS), and Merck & Co. (MRK), making waves in…

Bristol Myers Squibb (BMY) reports strong Q4 results, faces biosimilar competition, but shows growth potential.

Despite economic pressures and intensified competition, government incentives and drug innovations are fueling growth in the pharma sector. So, let us delve into the analysis of leading pharma stocks Bristol-Myers Squibb (BMY), Collegium Pharmaceutical (COLL), Pfizer (PFE), and Vaxcyte (PCVX), assessing whether to Grab, Hold, or Sell the stocks amid…

The pharma industry is experiencing significant growth, fueled by rising demand for personalized medicines, a revolutionary wave of drug development and robust government support. Therefore, it could be wise to consider fundamentally strong pharma stocks Zoetis (ZTS), Bristol-Myers Squibb (BMY), and Teva Pharmaceutical Industries (TEVA) to guard your portfolio. Read…

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.